Brain cancer device combo study pulled before it started
NCT ID NCT04129515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a device called NovoTTF-200A (which uses electric fields to disrupt cancer cells) together with the drug pembrolizumab in people with melanoma that had spread to the brain. The goal was to see if the combination was safe and effective. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma